[go: up one dir, main page]

SG11201700734RA - Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them - Google Patents

Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Info

Publication number
SG11201700734RA
SG11201700734RA SG11201700734RA SG11201700734RA SG11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA
Authority
SG
Singapore
Prior art keywords
methyl
tetrahydroquinoline
triazol
fluorophenyl
carboxylate
Prior art date
Application number
SG11201700734RA
Inventor
Mark Henderson
Colm Campbell
Carsten Jagusch
Christian Klaus Herz
Nico Bauer
Thierry Bonnaud
Olivier Lambert
Original Assignee
Medivation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies Inc filed Critical Medivation Technologies Inc
Publication of SG11201700734RA publication Critical patent/SG11201700734RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201700734RA 2014-07-31 2015-07-30 Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them SG11201700734RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462031521P 2014-07-31 2014-07-31
PCT/US2015/042867 WO2016019125A1 (en) 2014-07-31 2015-07-30 Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Publications (1)

Publication Number Publication Date
SG11201700734RA true SG11201700734RA (en) 2017-02-27

Family

ID=55218310

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700734RA SG11201700734RA (en) 2014-07-31 2015-07-30 Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Country Status (15)

Country Link
US (3) US20170217921A1 (en)
EP (1) EP3174855B1 (en)
JP (4) JP2017523243A (en)
KR (1) KR20170038850A (en)
CN (1) CN107155326B (en)
AU (1) AU2015296289B2 (en)
BR (1) BR112017001977A2 (en)
CA (1) CA2956714A1 (en)
EA (1) EA201790290A1 (en)
ES (1) ES2947501T3 (en)
IL (1) IL250365B (en)
MX (1) MX389260B (en)
SG (1) SG11201700734RA (en)
TW (1) TWI693214B (en)
WO (1) WO2016019125A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2767537T1 (en) 2008-08-06 2017-08-31 Medivation Technologies, Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
CN102869258A (en) 2010-02-03 2013-01-09 生物马林药物股份有限公司 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
AU2011213584B2 (en) 2010-02-08 2016-05-12 Medivation Technologies Llc Processes of synthesizing dihydropyridophthalazinone derivatives
PT2630146T (en) 2010-10-21 2020-07-20 Medivation Tech Llc Crystaline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one tosylate salt
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
EP3694551A1 (en) 2017-10-13 2020-08-19 Merck Patent GmbH Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW201938165A (en) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 Methods and combination therapy to treat cancer
EP3876940A1 (en) 2018-11-05 2021-09-15 Pfizer Inc. Combinations for treating cancer
JP2023517044A (en) 2020-03-09 2023-04-21 ファイザー・インク Fusion proteins and uses thereof
US20230414522A1 (en) 2020-11-13 2023-12-28 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
CN116802321A (en) 2020-12-07 2023-09-22 辉瑞公司 Methods to identify tumors that are sensitive to talazopanib treatment and how to treat them
BR112023018906A2 (en) 2021-03-24 2023-10-10 Astellas Pharma Inc COMBINATION OF TALAZOPARIB AND AN ANTIANDROGEN FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH MUTATION IN THE DDR GENE
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
TW202425975A (en) 2022-10-02 2024-07-01 美商輝瑞大藥廠 Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
TW202425976A (en) 2022-12-17 2024-07-01 美商輝瑞大藥廠 Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852253A (en) * 1981-09-21 1983-03-28 Tanabe Seiyaku Co Ltd P-hydroxyphenylglycine-alpha-phenylethanesulfonic acid salt and its optical resolution
US4415504A (en) * 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS63192753A (en) * 1987-02-05 1988-08-10 Otsuka Pharmaceut Co Ltd Optical resolution of tetrahydroquinoline derivative
JPH08322591A (en) * 1995-06-02 1996-12-10 Sumitomo Pharmaceut Co Ltd Method for obtaining optically pure 1,2,3,4-tetrahydroquinoline-2-acetic acid esters by optical resolution
AU2007358076A1 (en) * 2007-08-22 2009-02-26 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (Eg5 )
CN101298452A (en) * 2008-06-30 2008-11-05 南京华威医药科技开发有限公司 Preparing methods and uses of S-(-)-nadifloxacin and water soluble salt thereof
SI2767537T1 (en) * 2008-08-06 2017-08-31 Medivation Technologies, Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
MX2011001563A (en) * 2008-08-12 2011-03-04 Boehringer Ingelheim Int Process for preparing cycloalkyl-substituted piperazine compounds.
AU2011213584B2 (en) * 2010-02-08 2016-05-12 Medivation Technologies Llc Processes of synthesizing dihydropyridophthalazinone derivatives
PT2630146T (en) 2010-10-21 2020-07-20 Medivation Tech Llc Crystaline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one tosylate salt
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma

Also Published As

Publication number Publication date
IL250365A0 (en) 2017-03-30
EP3174855A4 (en) 2018-03-21
EP3174855A1 (en) 2017-06-07
US20210094930A1 (en) 2021-04-01
BR112017001977A2 (en) 2017-11-21
MX389260B (en) 2025-03-20
EP3174855B1 (en) 2023-05-10
NZ728634A (en) 2021-09-24
AU2015296289A1 (en) 2017-03-02
WO2016019125A1 (en) 2016-02-04
EA201790290A1 (en) 2017-07-31
JP2017523243A (en) 2017-08-17
US20190106401A1 (en) 2019-04-11
JP2024123096A (en) 2024-09-10
CN107155326B (en) 2021-03-05
TW201617319A (en) 2016-05-16
US20170217921A1 (en) 2017-08-03
IL250365B (en) 2021-02-28
KR20170038850A (en) 2017-04-07
TWI693214B (en) 2020-05-11
AU2015296289B2 (en) 2020-02-27
MX2017001416A (en) 2017-05-19
ES2947501T3 (en) 2023-08-10
CN107155326A (en) 2017-09-12
CA2956714A1 (en) 2016-02-04
JP2022116288A (en) 2022-08-09
JP2020125303A (en) 2020-08-20

Similar Documents

Publication Publication Date Title
IL250365B (en) Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
IL289099A (en) Methods for the storage of whole blood, and compositions thereof
HK1231377A1 (en) Pharmaceutical composition containing quinoline derivative or salt thereof, and preparation method therefor
EP3286996A4 (en) Extended-type subsoiling powder ridge machine and subsoiling powder ridge machine
IL247833A0 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
HUE049952T2 (en) Pyrazolone compound or salt thereof, preparation method therefor, herbicide composition and use thereof
IL259711A (en) Protein kinase inhibitor, preparation method and medical use thereof
SG10202102822RA (en) Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
EP3115361A4 (en) Heterocyclic compounds, and preparation method and use thereof
ZA201606386B (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
PL3388420T3 (en) Quinoline compounds, preparation method thereof, and use thereof as urate transporter inhibitor drug
EP3109240A4 (en) Triazine compound and use thereof for medical purposes
PT3527552T (en) Fused tricyclic -amino acid derivative, preparation method therefor, and medical use thereof
SG11201709414XA (en) Powdered titanium oxide, method for the production thereof, and use thereof
EP3261580A4 (en) Dental implant identification system
HK1250662A1 (en) Immunogenic fusion proteins for the treatment of cancer
EP3171840A4 (en) Improved medical implant
EP3118244A4 (en) Novel cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same
HRP20200104T8 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
MX2017007259A (en) Metal salt compositions.
GB201714060D0 (en) Method for preparing itraconazole preparation
EP3115367A4 (en) Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom
EP3231455A4 (en) Biocompatible composition and method for preparing same
EP3127903A4 (en) 2,2'-tandem dithiazole compound, preparation method therefor, and use thereof
AU2015900637A0 (en) Dental Implant Identification System